Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 11Sarcoma 6Neoplasms 6Lymphoma, Mantle-Cell 6Prostatic Neoplasms 5Lymphoma, Non-Hodgkin 5Rhabdomyosarcoma 4Neoplasm Metastasis 4Kidney Neoplasms 4Gliosarcoma 4Glioblastoma 4Breast Neoplasms 4Brain Neoplasms 4Waldenstrom Macroglobulinemia 3Osteosarcoma 3Melanoma 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Endometrial Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Oligodendroglioma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Liposarcoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Glioma 2Fallopian Tube Neoplasms 2Carcinoma, Hepatocellular 2

Interventions

Everolimus 4Temozolomide 3Octreotide 2Capecitabine 2Bevacizumab 2temsirolimus 1regorafenib 1pazopanib 1motesanib diphosphate 1folfirinox 1cixutumumab 1batifiban 1Sunitinib 1Sorafenib 1Sirolimus 1Oxaliplatin 1Leucovorin 1Granulocyte Colony-Stimulating Factor 1Fluorouracil 1Filgrastim 1Fentanyl 1Doxorubicin 1Cytokines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Islet Cell × temsirolimus × Clear all
NCT00093782 2017-02-07

Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 2 Completed
36 enrolled 12 charts

Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡